Dmitry I Gabrilovich

List of Publications by Year
in descending order

215 papers	59,179 citations	2802 94 h-index	1934 207 g-index
218 all docs	218 docs citations	218 times ranked	43305 citing authors

#	Article	IF	Citations
1	Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology, 2009, 9, 162-174.	22.7	5,655
2	Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 2018, 24, 541-550.	30.7	3,421
3	Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology, 2012, 12, 253-268.	22.7	3,002
4	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications, 2016, 7, 12150.	12.8	2,076
5	Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medicine, 1996, 2, 1096-1103.	30.7	1,721
6	The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends in Immunology, 2016, 37, 208-220.	6.8	1,507
7	Immunosuppressive Strategies that are Mediated by Tumor Cells. Annual Review of Immunology, 2007, 25, 267-296.	21.8	1,466
8	Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. Journal of Immunology, 2008, 181, 5791-5802.	0.8	1,447
9	Myeloid-Derived Suppressor Cells. Cancer Immunology Research, 2017, 5, 3-8.	3.4	1,345
10	Myeloid-derived suppressor cells coming of age. Nature Immunology, 2018, 19, 108-119.	14.5	1,285
11	Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer. Journal of Immunology, 2001, 166, 678-689.	0.8	1,214
12	Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Medicine, 2004, 10, 48-54.	30.7	1,029
13	Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nature Medicine, 2007, 13, 828-835.	30.7	1,000
14	History of myeloid-derived suppressor cells. Nature Reviews Cancer, 2013, 13, 739-752.	28.4	974
15	HIF-1Î± regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. Journal of Experimental Medicine, 2010, 207, 2439-2453.	8.5	966
16	Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Reviews Immunology, 2004, 4, 941-952.	22.7	920
17	Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo. Blood, 1998, 92, 4150-4166.	1.4	875
18	Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. Journal of Clinical Investigation, 2015, 125, 3356-3364.	8.2	846

#	Article	IF	Citations
19	Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. Journal of Experimental Medicine, 2008, 205, 2235-2249.	8.5	796
20	Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nature Reviews Immunology, 2021, 21, 485-498.	22.7	755
21	Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species. Journal of Immunology, 2004, 172, 989-999.	0.8	742
22	Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends in Immunology, 2011, 32, 19-25.	6.8	709
23	Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells. Journal of Immunology, 2009, 182, 5693-5701.	0.8	655
24	The Terminology Issue for Myeloid-Derived Suppressor Cells. Cancer Research, 2007, 67, 425-425.	0.9	649
25	MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis. Journal of Experimental Medicine, 2007, 204, 1463-1474.	8.5	581
26	Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Science Immunology, 2016, 1, .	11.9	560
27	Lipid accumulation and dendritic cell dysfunction in cancer. Nature Medicine, 2010, 16, 880-886.	30.7	539
28	All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients. Cancer Research, 2006, 66, 9299-9307.	0.9	506
29	Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells. Journal of Immunology, 2001, 166, 5398-5406.	0.8	500
30	The biology of myeloidâ€derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. European Journal of Immunology, 2010, 40, 2969-2975.	2.9	497
31	VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood, 2003, 101, 4878-4886.	1.4	465
32	Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Journal of Leukocyte Biology, 2011, 91, 167-181.	3.3	457
33	Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell, 2017, 32, 654-668.e5.	16.8	457
34	Fatty acid transport proteinÂ2 reprograms neutrophils in cancer. Nature, 2019, 569, 73-78.	27.8	440
35	Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer. Journal of Immunology, 2004, 172, 464-474.	0.8	418
36	Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. Journal of Clinical Investigation, 2010, 120, 1111-1124.	8.2	406

#	Article	IF	Citations
37	Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells. Annual Review of Medicine, 2015, 66, 97-110.	12.2	406
38	Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 878-887.	7.0	397
39	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
40	STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion. Journal of Immunology, 2005, 174, 4880-4891.	0.8	390
41	Mechanism of All-<i>Trans</i>Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells. Cancer Research, 2007, 67, 11021-11028.	0.9	367
42	All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Research, 2003, 63, 4441-9.	0.9	350
43	Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells. Journal of Immunology, 2010, 184, 3106-3116.	0.8	342
44	Dendritic cells in cancer: the role revisited. Current Opinion in Immunology, 2017, 45, 43-51.	5.5	339
45	Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer. Cancer Immunology, Immunotherapy, 2006, 55, 237-245.	4.2	323
46	Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 2005, 7, 457-468.	16.8	311
47	Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nature Immunology, 2013, 14, 211-220.	14.5	306
48	CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity, 2016, 44, 303-315.	14.3	299
49	Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nature Chemical Biology, 2020, 16, 278-290.	8.0	299
50	Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. Journal of Clinical Investigation, 2011, 121, 4015-4029.	8.2	298
51	Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells. Journal of Immunology, 2005, 175, 4583-4592.	0.8	297
52	Tumor Escape Mechanism Governed by Myeloid-Derived Suppressor Cells. Cancer Research, 2008, 68, 2561-2563.	0.9	292
53	Immature myeloid cells and cancer-associated immune suppression. Cancer Immunology, Immunotherapy, 2002, 51, 293-298.	4.2	289
54	Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 5187-5201.	7.0	288

#	Article	IF	Citations
55	ER stress regulates myeloid-derived suppressor cell fate through TRAIL-Râ€"mediated apoptosis. Journal of Clinical Investigation, 2014, 124, 2626-2639.	8.2	286
56	Plasticity of myeloid-derived suppressor cells in cancer. Current Opinion in Immunology, 2018, 51, 76-82.	5.5	281
57	Transcriptional regulation of myeloid-derived suppressor cells. Journal of Leukocyte Biology, 2015, 98, 913-922.	3.3	276
58	Regulation of Dendritic Cell Differentiation and Antitumor Immune Response in Cancer by Pharmacologic-Selective Inhibition of the Janus-Activated Kinase 2/Signal Transducers and Activators of Transcription 3 Pathway. Cancer Research, 2005, 65, 9525-9535.	0.9	273
59	Hypoxiaâ€inducible factors in regulation of immune responses in tumour microenvironment. Immunology, 2014, 143, 512-519.	4.4	270
60	Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunology, Immunotherapy, 2013, 62, 909-918.	4.2	268
61	Induction of myelodysplasia by myeloid-derived suppressor cells. Journal of Clinical Investigation, 2013, 123, 4595-4611.	8.2	254
62	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research, 2018, 24, 5347-5356.	7.0	253
63	Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer. Clinical Cancer Research, 2010, 16, 1812-1823.	7.0	252
64	Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood, 2004, 103, 3503-3510.	1.4	251
65	Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. Journal of Leukocyte Biology, 2003, 74, 186-196.	3.3	242
66	Dendritic Cells in Antitumor Immune Responses. Cellular Immunology, 1996, 170, 101-110.	3.0	230
67	Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells. Seminars in Immunology, 2018, 35, 19-28.	5.6	230
68	Notch-1 Regulates NF-Î°B Activity in Hemopoietic Progenitor Cells. Journal of Immunology, 2001, 167, 4458-4467.	0.8	207
69	Myeloid-Derived Suppressor Cells in Human Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 348-353.	2.0	203
70	Oxidized Lipids Block Antigen Cross-Presentation by Dendritic Cells in Cancer. Journal of Immunology, 2014, 192, 2920-2931.	0.8	203
71	Dendritic Cells in Antitumor Immune Responses. Cellular Immunology, 1996, 170, 111-119.	3.0	199
72	Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nature Communications, 2017, 8, 2122.	12.8	196

#	Article	IF	Citations
73	Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling. Journal of Immunology, 2005, 175, 4338-4346.	0.8	189
74	A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nature Genetics, 1996, 13, 210-213.	21.4	186
75	Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor. Journal of Clinical Oncology, 2008, 26, 3235-3241.	1.6	178
76	Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow. Journal of Immunology, 2013, 190, 3815-3823.	0.8	176
77	Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses. Clinical Cancer Research, 2007, 13, 4840-4848.	7.0	171
78	Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood, 2008, 111, 2220-2229.	1.4	171
79	Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer and Metastasis Reviews, 2006, 25, 323-331.	5.9	170
80	Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells. Journal of Immunology, 2013, 191, 17-23.	0.8	156
81	Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation. Nature Medicine, 2018, 24, 224-231.	30.7	150
82	Unique pattern of neutrophil migration and function during tumor progression. Nature Immunology, 2018, 19, 1236-1247.	14.5	140
83	Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody. Clinical Cancer Research, 2017, 23, 2942-2950.	7.0	137
84	Combination of ?-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: Approach to treatment of advanced stage cancer. International Journal of Cancer, 2001, 94, 825-833.	5.1	128
85	Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. Journal of Experimental Medicine, 2021, 218, .	8.5	123
86	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	4.6	119
87	A neuronal network of mitochondrial dynamics regulates metastasis. Nature Communications, 2016, 7, 13730.	12.8	112
88	Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Laboratory Investigation, 2011, 91, 598-608.	3.7	111
89	Combination of External Beam Radiotherapy (EBRT) With Intratumoral Injection of Dendritic Cells as Neo-Adjuvant Treatment of High-Risk Soft Tissue Sarcoma Patients. International Journal of Radiation Oncology Biology Physics, 2012, 82, 924-932.	0.8	109
90	INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opinion on Biological Therapy, 2010, 10, 983-991.	3.1	107

#	Article	IF	Citations
91	Molecular Pathways: Tumor-Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment. Clinical Cancer Research, 2012, 18, 4877-4882.	7.0	107
92	Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. Science Translational Medicine, 2020, 12, .	12.4	107
93	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nature Communications, 2021, 12, 346.	12.8	107
94	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood, 2015, 126, 1621-1628.	1.4	104
95	Î”Np63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. Journal of Clinical Investigation, 2018, 128, 5095-5109.	8.2	102
96	Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. Cell Reports, 2020, 33, 108571.	6.4	99
97	Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Molecular Immunology, 2015, 63, 579-585.	2.2	98
98	Antigen-Specific CD4+ T Cells Regulate Function of Myeloid-Derived Suppressor Cells in Cancer via Retrograde MHC Class II Signaling. Cancer Research, 2012, 72, 928-938.	0.9	96
99	Notch and Wingless Signaling Cooperate in Regulation of Dendritic Cell Differentiation. Immunity, 2009, 30, 845-859.	14.3	95
100	Highlights of 10 years of immunology in Nature Reviews Immunology. Nature Reviews Immunology, 2011, 11, 693-702.	22.7	95
101	Myeloid-Derived Suppressor Cells in the Development of Lung Cancer. Cancer Immunology Research, 2014, 2, 50-58.	3.4	95
102	Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic. Cancer Discovery, 2021, 11, 2693-2706.	9.4	89
103	HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. Cancer Research, 2019, 79, 5482-5489.	0.9	86
104	Notch signaling is necessary but not sufficient for differentiation of dendritic cells. Blood, 2003, 102, 3980-3988.	1.4	85
105	Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. Journal of Experimental Medicine, 2019, 216, 2150-2169.	8.5	85
106	The Ratio of Peripheral Regulatory T Cells to Lox-1⁺ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Antiâ€“PD-1 Therapy in Patients with Nonâ€“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 243-246.	5.6	85
107	BTN3A1 governs antitumor responses by coordinating Î±Î² and Î³Î´ T cells. Science, 2020, 369, 942-949.	12.6	83
108	Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clinical Cancer Research, 2003, 9, 285-94.	7.0	83

#	Article	IF	Citations
109	Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy. Cancer Research, 2012, 72, 5483-5493.	0.9	81
110	Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunology, Immunotherapy, 2013, 62, 405-410.	4.2	81
111	Effects of Notch Signaling on Regulation of Myeloid Cell Differentiation in Cancer. Cancer Research, 2014, 74, 141-152.	0.9	80
112	Genetic Immunotherapy of Established Tumors with Adenovirus-Murine Granulocyte-Macrophage Colony-Stimulating Factor. Human Gene Therapy, 1997, 8, 187-193.	2.7	78
113	Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34+ progenitor cells. Human Immunology, 2001, 62, 332-341.	2.4	78
114	Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands. Blood, 2007, 109, 507-515.	1.4	78
115	Full-length dominant-negative survivin for cancer immunotherapy. Clinical Cancer Research, 2003, 9, 6523-33.	7.0	78
116	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. Cancer Discovery, 2020, 10, 1282-1295.	9.4	75
117	Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. JCI Insight, 2020, 5, .	5.0	72
118	Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncology, The, 2007, 8, 2-3.	10.7	69
119	Tumor Escape from Immune Response: Mechanisms and Targets of Activity. Current Drug Targets, 2003, 4, 525-536.	2.1	67
120	Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunology, Immunotherapy, 2008, 57, 1523-1529.	4.2	67
121	EGR1 is a gatekeeper of inflammatory enhancers in human macrophages. Science Advances, 2021, 7, .	10.3	67
122	Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. Seminars in Cancer Biology, 2012, 22, 282-288.	9.6	65
123	Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17â€"producing CD4+ T cells. Journal of Experimental Medicine, 2015, 212, 351-367.	8.5	65
124	ICAM-1 controls development and function of ILC2. Journal of Experimental Medicine, 2018, 215, 2157-2174.	8.5	62
125	Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice. Biology of Blood and Marrow Transplantation, 2013, 19, 692-702.	2.0	61
126	Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells. Journal of Virology, 2001, 75, 7621-7628.	3.4	60

#	Article	IF	Citations
127	Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy. Cancer Letters, 2016, 371, 117-124.	7.2	59
128	Lactoferrin-induced myeloid-derived suppressor cell therapy attenuates pathologic inflammatory conditions in newborn mice. Journal of Clinical Investigation, 2019, 129, 4261-4275.	8.2	59
129	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Antiâ€“PD-(L)1 Therapy. Clinical Cancer Research, 2021, 27, 1019-1028.	7.0	58
130	Structural and functional analysis of Î²2 microglobulin abnormalities in human lung and breast cancer. , 1996, 67, 756-763.		57
131	INGN 201 (AdvexinÂ®): adenoviral p53 gene therapy for cancer. Expert Opinion on Biological Therapy, 2006, 6, 823-832.	3.1	56
132	Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunology, Immunotherapy, 2011, 60, 419-423.	4.2	56
133	CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight, 2018, 3, .	5.0	56
134	Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nature Communications, 2021, 12, 1717.	12.8	53
135	Regulation of dendritic cell differentiation and function by Notch and Wnt pathways. Immunological Reviews, 2010, 234, 105-119.	6.0	52
136	Targeting of Jak/STAT Pathway in Antigen Presenting Cells in Cancer. Current Cancer Drug Targets, 2007, 7, 71-77.	1.6	48
137	Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Research, 2018, 78, 4215-4228.	0.9	47
138	Upregulation of C/EBPÎ± Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. Clinical Cancer Research, 2021, 27, 5961-5978.	7.0	47
139	Phosphorylation of IRE1 at S729 regulates RIDD in B cells and antibody production after immunization. Journal of Cell Biology, 2018, 217, 1739-1755.	5.2	46
140	Tumor-Induced STAT3 Signaling in Myeloid Cells Impairs Dendritic Cell Generation by Decreasing PKCÎ²II Abundance. Science Signaling, 2014, 7, ra16.	3.6	45
141	Notch signaling in differentiation and function of dendritic cells. Immunologic Research, 2008, 41, 1-14.	2.9	44
142	PPT1 inhibition enhances the antitumor activity of antiâ€“PD-1 antibody in melanoma. JCI Insight, 2020, 5, .	5.0	44
143	Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor. Clinical and Experimental Metastasis, 1999, 17, 881-888.	3.3	43
144	Developing dendritic cells become 'lacy' cells packed with fat and glycogen. Immunology, 2005, 115, 473-483.	4.4	42

#	Article	IF	Citations
145	Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	41
146	Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma. Journal of Immunotherapy, 2010, 33, 817-827.	2.4	40
147	Combined Inhibition of Notch Signaling and Bcl-2/Bcl-xL Results in Synergistic Antimyeloma Effect. Molecular Cancer Therapeutics, 2010, 9, 3200-3209.	4.1	40
148	Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunology, Immunotherapy, 2014, 63, 1009-1021.	4.2	40
149	Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice. Cancer Research, 2018, 78, 5644-5655.	0.9	40
150	Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. Cancer Immunology, Immunotherapy, 2019, 68, 517-527.	4.2	39
151	Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors. Cancer Immunology, Immunotherapy, 2020, 69, 1929-1936.	4.2	39
152	H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. Journal of Leukocyte Biology, 2002, 72, 285-96.	3.3	38
153	Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer. Journal of Clinical Investigation, 2017, 127, 3755-3769.	8.2	37
154	Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. OncoTargets and Therapy, 2017, Volume 10, 4239-4250.	2.0	36
155	â€œRedox lipidomics technology: Looking for a needle in a haystackâ€• Chemistry and Physics of Lipids, 2019, 221, 93-107.	3.2	35
156	MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer. Cancer Research, 2019, 79, 6215-6226.	0.9	34
157	Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy, 2012, 4, 373-382.	2.0	33
158	â€œOnly a Life Lived for Others Is Worth Livingâ€• Redox Signaling by Oxygenated Phospholipids in Cell Fate Decisions. Antioxidants and Redox Signaling, 2018, 29, 1333-1358.	5.4	33
159	Activation of p38Î± stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs. Nature Cancer, 2020, 1, 603-619.	13.2	33
160	ICAM-1 Deficiency in the Bone Marrow Niche Impairs Quiescence andÂRepopulation of Hematopoietic Stem Cells. Stem Cell Reports, 2018, 11, 258-273.	4.8	32
161	Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. IScience, 2021, 24, 102016.	4.1	32
162	Myeloid-Derived Suppressor Cells and Radiotherapy. Cancer Immunology Research, 2022, 10, 545-557.	3.4	32

#	Article	IF	Citations
163	Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis. Molecular and Cellular Biology, 2019, 39, .	2.3	31
164	Transcriptional factor ATF3 protects against colitis by regulating follicular helper T cells in Peyerâ€™s patches. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6286-6291.	7.1	30
165	Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. Drug Resistance Updates, 2008, 11, 210-218.	14.4	27
166	Molecular speciation and dynamics of oxidized triacylglycerols in lipid droplets: Mass spectrometry and coarse-grained simulations. Free Radical Biology and Medicine, 2014, 76, 53-60.	2.9	26
167	Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. Journal of Clinical Investigation, 2020, 130, 2789-2799.	8.2	26
168	Clinical Significance of Neutrophil Functional Activity in HIV Infection. Scandinavian Journal of Infectious Diseases, 1994, 26, 41-47.	1.5	25
169	Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. Cancer Immunology, Immunotherapy, 2012, 61, 573-579.	4.2	25
170	Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth. Journal of Biological Chemistry, 2019, 294, 10407-10414.	3.4	25
171	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. Clinical Cancer Research, 2019, 25, 2783-2794.	7.0	25
172	Murine Retrovirus Induces Defects in the Function of Dendritic Cells at Early Stages of Infection. Cellular Immunology, 1994, 158, 167-181.	3.0	23
173	Dendritic cell vaccines for cancer treatment. Current Opinion in Molecular Therapeutics, 2002, 4, 452-8.	2.8	23
174	Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice. Cancer Immunology Research, 2018, 6, 696-710.	3.4	21
175	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nature Communications, 2021, 12, 6023.	12.8	21
176	ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells. Cancer Cell, 2015, 28, 147-149.	16.8	20
177	COX-1â€“derived thromboxane A2 plays an essential role in early B-cell development via regulation of JAK/STAT5 signaling in mouse. Blood, 2014, 124, 1610-1621.	1.4	18
178	Molecular mechanisms and therapeutic reversal of immune suppression in cancer. Current Cancer Drug Targets, 2007, 7, 1.	1.6	18
179	Immune Tolerance in Breast Cancer. Breast Disease, 2004, 20, 93-103.	0.8	16
180	Regulation of Dendritic Cell Differentiation in Bone Marrow during Emergency Myelopoiesis. Journal of Immunology, 2013, 191, 1916-1926.	0.8	16

#	Article	IF	Citations
181	Regulation of plasmacytoid dendritic cell development in mice by aryl hydrocarbon receptor. Immunology and Cell Biology, 2014, 92, 200-203.	2.3	16
182	Mass-spectrometric characterization of peroxidized and hydrolyzed lipids in plasma and dendritic cells of tumor-bearing animals. Biochemical and Biophysical Research Communications, 2011, 413, 149-153.	2.1	15
183	A Novel Inhibitor of HSP70 Induces Mitochondrial Toxicity and Immune Cell Recruitment in Tumors. Cancer Research, 2020, 80, 5270-5281.	0.9	15
184	Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity. Cancer Research, 2021, 81, 658-670.	0.9	15
185	Cellular immunotherapy for soft tissue sarcomas. Immunotherapy, 2012, 4, 283-290.	2.0	14
186	Myeloid Cellâ€“Derived Oxidized Lipids and Regulation of the Tumor Microenvironment. Cancer Research, 2022, 82, 187-194.	0.9	14
187	The Dawn of Myeloid-Derived Suppressor Cells: Identification of Arginase I as the Mechanism of Immune Suppression. Cancer Research, 2021, 81, 3953-3955.	0.9	12
188	Effects of murine leukemia viruses on the function of dendritic cells. European Journal of Immunology, 1993, 23, 2932-2938.	2.9	11
189	The role of mannose-6-phosphate receptor and autophagy in influencing the outcome of combination therapy. Autophagy, 2013, 9, 615-616.	9.1	11
190	New roles of Rb1 in expansion of MDSCs in cancer. Cell Cycle, 2013, 12, 1329-1330.	2.6	10
191	Can the Suppressive Activity of Myeloid-Derived Suppressor Cells Be â€œChopâ€ped?. Immunity, 2014, 41, 341-342.	14.3	10
192	All Myeloid-Derived Suppressor Cells Are Not Created Equal: How Gender Inequality Influences These Cells and Affects Cancer Therapy. Cancer Discovery, 2020, 10, 1100-1102.	9.4	7
193	Comment on â€œCutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cellsâ€. Journal of Immunology, 2007, 178, 4705.2-4706.	0.8	6
194	Editorial: The intricacy of choice: can bacteria decide what type of myeloid cells to stimulate?. Journal of Leukocyte Biology, 2014, 96, 671-674.	3.3	6
195	Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS).. Blood, 2009, 114, 597-597.	1.4	6
196	Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC). Blood, 2011, 118, 788-788.	1.4	6
197	Î²1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation. Oncotarget, 2016, 7, 52618-52630.	1.8	6
198	A Bayesian pick-the-winner design in a randomized phase II clinical trial. Oncotarget, 2017, 8, 88376-88385.	1.8	6

#	Article	IF	Citations
199	ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts. Journal of Cancer, 2022, 13, 1933-1944.	2.5	6
200	Detecting Prostate Cancer Using Pattern Recognition Neural Networks With Flow Cytometry-Based Immunophenotyping in At-Risk Men. Biomarker Insights, 2020, 15, 117727192091332.	2.5	5
201	Development of vaccines against self-antigens: the p53 paradigm. Current Opinion in Drug Discovery & Development, 2003, 6, 169-73.	1.9	5
202	Isolation and Phenotyping of Splenic Myeloid-Derived Suppressor Cells in Murine Cancer Models. Methods in Molecular Biology, 2021, 2236, 19-28.	0.9	4
203	Fatal attraction: How macrophages participate in tumor metastases. Journal of Experimental Medicine, 2015, 212, 976-976.	8.5	3
204	A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma. Blood, 2014, 124, 5729-5729.	1.4	3
205	Applying Pressure on Macrophages. Immunity, 2013, 38, 205-206.	14.3	2
206	Biology of Myeloid-Derived Suppressor Cells. , 2018, , 181-197.		2
207	Recent Advances in Immunotherapy of Lung Cancer. Journal of Lung Cancer, 2012, 11, 1.	0.2	1
208	Mechanisms regulating transitory suppressive activity of neutrophils in newborns: PMNsâ€MDSCs in newborns. Journal of Leukocyte Biology, 0, , .	3.3	1
209	M17-02: Immunotherapy of extensive stage small cell lung cancer with dendritic cell based p53 vaccine. Journal of Thoracic Oncology, 2007, 2, S198-S199.	1.1	0
210	Editorial overview: Many shades of grey: how immune response is regulated by tumors. Current Opinion in Immunology, 2017, 45, ix-xi.	5.5	0
211	A New Target in Multiple Myeloma: Inhibition of Notch Pathway Induces Apoptosis and Enhances Drug Sensitivity of Myeloma Cells In Vitro and In Vivo.. Blood, 2006, 108, 841-841.	1.4	0
212	Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy. Blood, 2008, 112, 4653-4653.	1.4	0
213	Novel Role of Histone Deacetylase 11 (HDAC11) in Hematopoiesis. Blood, 2012, 120, 4728-4728.	1.4	0
214	Accumulation of Myeloid-Derived Suppressor Cells in Bone Marrow in Multiple Myeloma Induces Tumor-Specific Immune Suppression and Promotes Tumor Growth. Blood, 2012, 120, 3954-3954.	1.4	0
215	Dynamic Changes and Impact of Myeloid Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice.. Blood, 2012, 120, 2999-2999.	1.4	0